Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.61 |
| ▸ | PTGES | O14684 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426104 | 0.88 | PTGS2 (0.63) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL20429507 | 0.87 | PTGS2 (0.71) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL4587742 | 0.86 | PTGS2 (0.60) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL4588503 | 0.85 | PTGS2 (0.86) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL5344449 | 0.85 | PTGS1 (0.80) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL8221226 | 0.84 | PTGS2 (0.56) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL4586553 | 0.84 | PTGS2 (0.65) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL8266070 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL4588678 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL14561986 | 0.83 | HDAC3 (0.62) | PTGS2PTGS1CYP2C9PDPK1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377289-A4 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | JB CHEMICALS & PHARMACEUTICALS (IN) | 2008-09-10 | — | — | EP | claimed |
| US-20050075359-A1 | Large conductance calcium-activated K channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2005-04-07 | — | — | US | claimed |
| EP-1400243-A1 | Calcium-activated K channel activator | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-24 | — | — | EP | claimed |
| EP-1377289-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. Chemicals & Pharmaceuticals Ltd. (IN) | 2004-01-07 | — | — | EP | claimed |
| WO-2002074235-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. CHEMICALS & PHARMACEUTICALS LTD (IN) | 2002-09-26 | — | — | WO | claimed |
| US-6403629-B2 | 1-(P-(METHYLSULFONAMIDO)PHENYL)-3-TRIFLUOROMETHYL-5-PHENYLPYRA ZOLONE AND DERIVATIVES; ANTIINFLAMMATORY AGENTS | J.B. CHEMICAL AND PHARMACEUTICALS LIMITED (IN) | 2002-06-11 | — | — | US | claimed |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | J.B. CHEMICALS & PHARMACEUTICALS LIMITED | 2001-11-29 | — | — | US | claimed |
| EP-1377289-A4 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | JB CHEMICALS & PHARMACEUTICALS (IN) | 2008-09-10 | — | — | EP | disclosed |
| EP-1377289-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. Chemicals & Pharmaceuticals Ltd. (IN) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002074235-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. CHEMICALS & PHARMACEUTICALS LTD (IN) | 2002-09-26 | — | — | WO | disclosed |
| US-6403629-B2 | 1-(P-(METHYLSULFONAMIDO)PHENYL)-3-TRIFLUOROMETHYL-5-PHENYLPYRA ZOLONE AND DERIVATIVES; ANTIINFLAMMATORY AGENTS | J.B. CHEMICAL AND PHARMACEUTICALS LIMITED (IN) | 2002-06-11 | — | — | US | disclosed |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | J.B. CHEMICALS & PHARMACEUTICALS LIMITED | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075359-A1 | Large conductance calcium-activated K channel opener | KCNN3, KCNN2, KCNN1 | PTGS2 806/4885PTGS1 760/4885CYP2C9 2086/4885 |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | AADAC, NAT1, FPR1 | PTGS2 352/4885PTGS1 94/4885CYP2C9 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.